US BROKER MOVES: ALB upgraded at Mizuho; DELL downgraded at Barclays
The October 14 broker-moves report lists upgrades, downgrades, and new coverage initiations, including analyst ratings and stated price targets.
News detail
UPGRADES: Albemarle (ALB) Upgraded from Neutral to Outperform at Mizuho; PT USD 130 Brinker International (EAT) Upgraded from Hold to Buy at Jefferies; PT USD 255 GXO Logistics (GXO) Upgraded from Neutral to Buy at Goldman Sachs; PT USD 61 Kontoor Brands (KTB) Upgraded from Hold to Buy at Jefferies; PT USD 89 Lockheed Martin (LMT) Upgraded from Hold to Buy at Vertical Research Partners; PT USD 600 Liquidia (LQDA) Upgraded from Neutral to Buy at BTIG; PT USD 70 Pentair (PNR) Upgraded from Sell to Hold at TD Cowen Ralliant (RAL) Upgraded from Neutral to Buy at Seaport Global Securities; PT USD 88 Tencent Music (TME) Upgraded from Hold to Buy at China Merchants Securities; PT USD 10.50 Trane Technologies (TT) Upgraded from Neutral to Buy at Goldman Sachs; PT USD 565 Texas Roadhouse (TXRH) Upgraded from Hold to Buy at Jefferies; PT USD 190 Western Union (WU) Upgraded from Sell to Neutral at Monness, Crespi, Hardt; PT USD 5 Weyerhaeuser (WY) Upgraded from Neutral to Buy at BofA Securities; PT USD 25 DOWNGRADES Albertsons (ACI) Downgraded from Neutral to Underperform at BofA Securities; PT USD 12 Bruker (BRKR) Downgraded from Overweight to Neutral at JPMorgan; PT USD 60 Carrier Global (CARR) Downgraded from Buy to Neutral at Goldman Sachs; PT USD 61 Chemours (CC) Downgraded from Outperform to Neutral at Mizuho; PT USD 15 Dell Technologies (DELL) Downgraded from Overweight to Equalweight at Barclays; PT USD 574 HPE (HPE) Downgraded from Overweight to Equalweight at Barclays; PT USD 77 Lennox International (LII) Downgraded from Buy to Neutral at Goldman Sachs; PT USD 390 NetApp (NTAP) Downgraded from Overweight to Equalweight at Barclays; PT USD 219 Safehold (SAFE) Downgraded from Market Outperform to Market Perform at Citizens Sotera Health (SHC) Downgraded from Neutral to Underweight at JPMorgan; PT USD 17 INITIATIONS Alcoa (AA) Initiated at Overweight at Barclays; PT USD 55 Ascentage Pharma Group Internat (AAPG) Initiated at Buy at Citi; PT USD 46 AGNT (AGNT) Initiated at Market Outperform at Citizens; PT USD 6 Amprius Technologies (AMPX) Initiated at Buy at Canaccord; PT USD 14 Aprea Therapeutics (APRE) Initiated at Buy at Ladenburg Thalmann; PT USD 2 Archimedes Tech SPAC Partners II Co. (ATII) Initiated at Overweight at Alembic Global Advisors; PT USD 16.29 AZZ (AZZ) Initiated at Equalweight at Barclays; PT USD 140 Century Aluminum (CENX) Initiated at Equalweight at Barclays; PT USD 40 Compass (COMP) Initiated at Market Outperform at Citizens; PT USD 11 Constellium (CSTM) Initiated at Equalweight at Barclays; PT USD 28 Douglas Elliman (DOUG) Initiated at Market Perform at Citizens Entegris (ENTG) Initiated at Buy at Truist Securities; PT USD 190 Garmin (GRMN) Initiated at Buy at Arete; PT USD 335 Innovative Industrial Properties (IIPR) Initiated at Buy at Stifel; PT USD 56.25 Jasper Therapeutics (JSPR) Initiated at Outperform at William Blair Kaiser Aluminum (KALU) Initiated at Overweight at Barclays; PT USD 180 Kirby (KEX) Initiated at Overweight at JPMorgan; PT USD 200 Marex (MRX) Initiated at Outperform at William Blair Qnity Electronics (Q) Initiated at Buy at Truist Securities; PT USD 170 QNB Corp (QNBC) Initiated at Buy at Brean Capital; PT USD 54 Arcus Biosciences (RCUS) Initiated at Overweight at JPMorgan; PT USD 41 Real Brokerage (REAX) Initiated at Market Outperform at Citizens; PT USD 40 Reliance (RS) Initiated at Equalweight at Barclays; PT USD 420 Sol-Gel Technologies (SLGL) Initiated at Overweight at Cantor Fitzgerald Seaport Therapeutics (SPTX) Initiated at Buy at Canaccord; PT USD 28 Standex International (SXI) Initiated at Neutral at JPMorgan; PT USD 320 Vylor (VYLR) Initiated at Buy at Deutsche Bank; PT USD 90 Vylor (VYLR) Initiated at Neutral at BNP Paribas Exane; PT USD 75
Related stocks
47 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
